Compare Amylx Pharmaceuticals Inc (AMLX) vs Krispy Kreme Inc (DNUT) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Amylx Pharmaceuticals Inc vs Krispy Kreme Inc — how do they compare? Amylx Pharmaceuticals Inc trades at $17.65 (market cap $1.98B), while Krispy Kreme Inc trades at $3.41 (market cap $593.06M). The key difference: Amylx Pharmaceuticals Inc is far larger — about 3.3× Krispy Kreme Inc's market cap, and Krispy Kreme Inc pays a 3.47% dividend while Amylx Pharmaceuticals Inc pays none. Which is the better fit depends on your goals.
| AMLX | DNUT | |
|---|---|---|
Market Cap | $1.98B | $593.06M |
Sector | Health | Consumer Staples |
52-Week High | $18.70 | $4.70 |
52-Week Low | $7.64 | $2.92 |
Enterprise Value | $1.70B | $1.79B |
Dividend Yield | — | 3.47% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
AMLX trades at $17.77, down 3.32% today, with a bullish technical signal from moving averages and strong analyst support. The company is in a pivotal phase with key Phase 3 data for avexitide expected in Q3 2026, targeting a potential 2027 launch. Financially, it shows significant losses with negative ROE and ROA, but cash flow from financing activities provides runway. Recent news highlights clinical progress and conference presentations, alongside ongoing class action settlement discussions.
The outlook hinges on successful clinical trial outcomes, particularly avexitide's Phase 3 readout, which could drive substantial upside toward the $30.50 consensus price target. However, high execution risk, persistent cash burn, and legal overhangs pose threats to near-term stability. Investor sentiment remains cautiously optimistic given the 90.9% buy rating from analysts, but the stock is speculative until profitability milestones are achieved.
Krispy Kreme (DNUT) trades at $3.44, up 0.58% today, amid bearish technical signals and mixed fundamentals. The stock shows negative profitability with a -33.36% net margin and -58.92% ROE, though revenue remains stable near $1.5B. Recent Q1 2026 earnings missed expectations, but Q3 and Q4 2025 beat forecasts. Analyst sentiment is cautiously optimistic with 50% buy ratings, while technical indicators point to resistance near $4.
Outlook hinges on execution of capital-light expansion and cost controls. Risks include persistent losses and high debt, but potential upside exists if turnaround initiatives boost margins. Investors should weigh analyst optimism against weak cash flow trends and competitive pressures in the consumer staples sector.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Amylx Pharmaceuticals Inc
Amylyx Pharmaceuticals is a biopharmaceutical firm focused on developing therapies for rare diseases. Its pipeline includes treatments for conditions like post-bariatric hypoglycemia and congenital hyperinsulinism.
Read more on AMLX →About Krispy Kreme Inc
Krispy Kreme Inc is a sweet treat brands company. The company's Original Glazed doughnut is recognized for its hot-off-the-line, melt-in- your-mouth experience. It operates in 30 countries through its network of fresh Doughnut Shops, partnerships with retailers, and a growing ecommerce and delivery business. The company conducts its business through the following three reported segments namely U.S. and Canada, includes all operations in the U.S. and Canada, Insomnia Cookies shops, and the Branded Sweet Treat Line
Read more on DNUT →
